Description

Contact hours available until 8/31/2015.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNEevaluation.

Authors Conflict of Interest Disclosure:
The author(s) reported no actual or potential conflict of interest in relationto this continuing nursing education activity.

Nephrology Nursing Journal Editorial Board Statements of Disclosure:
Deborah H. Brooks, MSN, APN-BC, CNNNP, disclosed that she is on the ConsultantPresenter Bureau and the Advisory Board for Affymax, Inc.

Paula Dutka, MSN, RN, CNN, disclosed that she has received grant/researchsupport from Keryx, Amgen, Rockwell, Fibrogen, Dynovox, and Otsuka; and she ison the Consultant and Presenter Bureau and the Nephrology Nurse Advisory Boardfor Affymax/Takeda.

Patricia B. McCarley, MSN, RN, ACNPc, CNN, disclosed that she is on theConsultant Presenter Bureau for Amgen, Genzyme, and
OrthoBiotech. She is also on the Advisory Board for Amgen, Genzyme, and Rocheand is the recipient of unrestricted educational grants from OrthoBiotech andRoche.

All other members of the Editorial Board had no actual or potential conflict ofinterest in relation to this continuing nursing education activity.

This article was reviewed and formatted for contact hour credit by Beth Ulrich,EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Hazel A. Dennison,DNP, RN, APNc, CPHQ, CNE, ANNA Education Director.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider ofcontinuing nursing education by the American Nurses Credentialing Center’sCommission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing,provider number CEP 00910.

Goal
To recognize accesses at-risk for fatal vascular access hemorrhage (FVAH) andimplement strategies to decrease FVAHs.

Objectives
1. Discuss current data relevant to fatal vascular access hemorrhage (FVAH)episodes.
2. Describe access assessment techniques to reduce the risk of developing anFVAH.
3. List three interventions that can reduce the risk of FVAH in accesses.